nalmefene nasal spray · OPVEE

Small molecule

Approved / Phase 4Opioid receptorNo featureable registry evidence
Approvedregulatory verdict

Evidence outlook

Approved: Opioid Overdose Reversal

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Every registered study for this drug was reviewed, and none was selected as featured evidence for its approved use, so its Featured trials section is empty.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.

No registered studies found. Not yet ingested, or none registered.

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Nalmefene Nasal Spray (OPVEE): this drugApprovedSmall moleculeOpioid receptornot yet gradedNo reviewed efficacy summary
Naloxone (Narcan)
Approved(overall)
Small moleculeOpioid receptornot yet gradedNo reviewed efficacy summary
Naltrexone (Vivitrol)
Approved(overall)
Small moleculeOpioid receptorPartial signalNo reviewed efficacy summary
Naltrexone / Acetaminophen (ALLOD-2)
Phase 2/3(overall)
—Opioid receptornot yet gradedNo reviewed efficacy summary

Upcoming events

No upcoming readouts on record for this asset.